On Thursday, March 1, Sanofi announced that it has received antitrust clearances in the US and Germany in connection with its proposed acquisition of Ablynx.
Sanofi said that a waiting period for its proposed acquisition of Ablynx had expired without objections being raised. Under the US Hart-Scott-Rodino Antitrust Improvements Act, parties to certain transactions must submit notification to the country’s Federal Trade Commission and Department of Justice and wait before the transaction can be completed.
The proposed acquisition has also been cleared by the Federal Cartel Office (FCO) of Germany, the French pharmaceutical company said.
With the expiration of the waiting period and the FCO clearance, “the condition to the offers relating to antitrust approvals has been satisfied,” Sanofi said.
Full Content: Market Watch
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
